They could do an RO on those still taking leronlimab being outside the study timeline it most likely wouldn't be judged as evidence. No longer on leronlimab would be useless unless they restarted on leronlimab but still not evidential.

Why the FDA think's RO is of utmost importance rather than efficacy seems like a boondoggle.